A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment. Axi-cel was approved by the U.S. Food and Drug Administration for treatment of DLBCL in October 2017 and by the European Commission in August 2018.
The study, co-led...
The University of Texas MD Anderson Cancer Center and the Houston Dynamo today announced plans to work together toward one goal: end cancer...
Two leaders in the field of melanoma treatment – a surgeon and an oncologist – from The University of Texas MD Anderson Cancer Center have...
Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new immunotherapies, will receive $1 million in initial funding from Stand Up to Cancer.
The project led by researchers from The University of Texas MD Anderson Cancer Center and Baylor College of Medicine will collect T cells – the immune system’s targeted warriors – from tumors, expand their...
The University of Texas MD Anderson Cancer Center applauds new actions announced today by the U.S. Food and Drug Administration (FDA) to limit...
A Phase I/II study, led by investigators at The University of Texas MD Anderson Cancer Center, reports an investigational drug called tagraxofusp...
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called...
The University of Texas MD Anderson Cancer Center today formally opened a four-story facility in League City that houses new and expanded...
For the first time, transplanting gut bacteria from healthy donors was used to successfully treat patients suffering from severe colitis caused...
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated...